Tu
No verificado

Tubulis

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaOncologíaSalud
21/01/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Industria
Tubulis Unveils Alco5 Conjugation Platform’s Ability to Expand ADC Payload Scope in Nature Communications
Fuente
1.00
08/01/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Mercado laboral
Tubulis Appoints Charles Fuchs, MD as Chief Medical Officer to Lead Clinical Strategy and Pipeline Development
Fuente
1.00
16/12/2025
Eventos
Sanidad
Salud
Farmacéutica
Medicina - Varios
Oncología
Tubulis to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fuente
1.00
30/10/2025
Biotecnología
Sanidad
Salud
Farmacéutica
Oncología
Ciencia
Ir de compras
Medicina - Varios
Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $401M)
Fuente
1.00
19/10/2025
Ciencia
Medicina - Varios
Biotecnología
Farmacéutica
Ir de compras
Salud
Oncología
Eventos
Industria
Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025
Fuente
1.00
15/10/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline
Fuente
1.00
22/09/2025
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Tubulis to Present First Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-Resistant Ovarian Cancer in Late-Breaking Oral Presentation at ESMO 2025
Fuente
1.00
09/09/2025
Ciencia
Legislación/Derecho
Biotecnología
Farmacéutica
Oncología
Salud
Asociaciones/Profesionales
Mercado laboral
Tubulis Strengthens Leadership Team with Appointment of Halley Gilbert as Chief Legal and Operating Officer
Fuente
1.00
06/02/2025
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.
Fuente
1.00
30/01/2025
Ciencia
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Oncología
Industria
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
Fuente
1.00

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0